MA49651A - Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte - Google Patents
Compositions et procédés pour traiter des maladies associées à un défaut d'empreinteInfo
- Publication number
- MA49651A MA49651A MA049651A MA49651A MA49651A MA 49651 A MA49651 A MA 49651A MA 049651 A MA049651 A MA 049651A MA 49651 A MA49651 A MA 49651A MA 49651 A MA49651 A MA 49651A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- diseases associated
- treating diseases
- impression
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534532P | 2017-07-19 | 2017-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49651A true MA49651A (fr) | 2021-04-28 |
Family
ID=65016147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049651A MA49651A (fr) | 2017-07-19 | 2018-07-19 | Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12178854B2 (fr) |
| EP (1) | EP3654956A4 (fr) |
| CN (1) | CN111132671B (fr) |
| MA (1) | MA49651A (fr) |
| WO (1) | WO2019018635A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102473092B1 (ko) | 2014-09-15 | 2022-12-01 | 칠드런'즈 메디컬 센터 코포레이션 | 히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물 |
| MA49651A (fr) | 2017-07-19 | 2021-04-28 | Childrens Medical Center | Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte |
| US20210155959A1 (en) * | 2018-04-06 | 2021-05-27 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
| KR102732761B1 (ko) * | 2018-07-19 | 2024-11-25 | 칠드런'즈 메디컬 센터 코포레이션 | 생리학적 x 염색체 불활성화를 생성하기 위한 조성물 및 방법 |
| CN113801851B (zh) * | 2020-06-17 | 2025-07-25 | 中国科学院动物研究所 | 一种体细胞核移植方法及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664097A (en) | 1984-05-09 | 1987-05-12 | The Wistar Institute Of Anatomy & Biology | Nuclear transplantation in the mammalian embryo by microsurgery and cell fusion |
| US4994384A (en) | 1986-12-31 | 1991-02-19 | W. R. Grace & Co.-Conn. | Multiplying bovine embryos |
| US5057420A (en) | 1987-06-05 | 1991-10-15 | Granada Biosciences, Inc. | Bovine nuclear transplantation |
| US6107543A (en) | 1992-08-20 | 2000-08-22 | Infigen, Inc. | Culture of totipotent embryonic inner cells mass cells and production of bovine animals |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB2331751B (en) | 1995-08-31 | 2000-01-19 | Roslin Inst | Quiescent cell populations for nuclear transfer |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US6011197A (en) | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
| US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
| CN1242061C (zh) | 2001-01-04 | 2006-02-15 | 上海交通大学 | 一种短指基因 |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| AU2012253359B2 (en) | 2011-05-11 | 2017-06-08 | Children's Medical Center Corporation | Multiple antigen presenting immunogenic composition, and methods and uses thereof |
| CA2887243C (fr) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methodes de traitement du cancer |
| WO2015048577A2 (fr) * | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Compositions et méthodes relatives aux répétitions palindromiques groupées, courtes et régulièrement espacées |
| KR20210117347A (ko) | 2013-12-06 | 2021-09-28 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| EP3111222A1 (fr) * | 2014-02-26 | 2017-01-04 | Glaxosmithkline Intellectual Property (No. 2) Limited | Méthodes de traitement de patients atteints de cancer réagissant à l'inhibiteur d'ezh2 gsk126 |
| MX394629B (es) | 2014-10-16 | 2025-03-24 | Epizyme Inc | Método para tratar el cáncer. |
| EP4309738A3 (fr) | 2015-10-06 | 2024-07-17 | Epizyme, Inc. | Procédé de traitement du médulloblastome avec un inhibiteur d'ezh2 |
| WO2017079738A1 (fr) | 2015-11-05 | 2017-05-11 | Epizyme, Inc. | Cytométrie de flux permettant de surveiller l'état de la méthylation d'une histone h3 |
| EP3386513A2 (fr) | 2015-12-07 | 2018-10-17 | Epizyme Inc | Inhibiteurs d'ezh2 et leur utilisation |
| MA49651A (fr) | 2017-07-19 | 2021-04-28 | Childrens Medical Center | Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte |
-
2018
- 2018-07-19 MA MA049651A patent/MA49651A/fr unknown
- 2018-07-19 CN CN201880060928.5A patent/CN111132671B/zh active Active
- 2018-07-19 WO PCT/US2018/042876 patent/WO2019018635A1/fr not_active Ceased
- 2018-07-19 US US16/631,762 patent/US12178854B2/en active Active
- 2018-07-19 EP EP18835463.3A patent/EP3654956A4/fr active Pending
-
2023
- 2023-06-26 US US18/341,584 patent/US20240000900A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019018635A1 (fr) | 2019-01-24 |
| CN111132671A (zh) | 2020-05-08 |
| EP3654956A4 (fr) | 2021-04-28 |
| US20200179491A1 (en) | 2020-06-11 |
| US20240000900A1 (en) | 2024-01-04 |
| CN111132671B (zh) | 2023-10-27 |
| EP3654956A1 (fr) | 2020-05-27 |
| US12178854B2 (en) | 2024-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| EP3890748A4 (fr) | Compositions et procédés de traitement de troubles hépatiques | |
| EP3869985A4 (fr) | Composition et méthode pour traiter les poumons | |
| EP3496739A4 (fr) | Compositions et procédés de traitement de l'hypertension pulmonaire | |
| EP3319976A4 (fr) | Compositions et procédés pour traiter des maladies pulmonaires et des lésions pulmonaires | |
| EP3701041A4 (fr) | Méthodes et compositions pour traiter des maladies associées à des lymphocytes t épuisés | |
| EP3635100A4 (fr) | Compositions et procédés pour exprimer l'otoferline | |
| MA49651A (fr) | Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte | |
| EP3612215A4 (fr) | Compositions et procédés pour le traitement d'inflammation pulmonaire | |
| EP3615016A4 (fr) | Procédés et compositions pour le traitement d'apnée du sommeil | |
| EP3273944A4 (fr) | Compositions et procédés permettant d'administrer des agents de type biomacromolécule | |
| EP3390642A4 (fr) | Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13 | |
| MA52134A (fr) | Compositions et procédés pour l'édition génomique | |
| EP3331542A4 (fr) | Compositions et procédés pour traiter des cancers associés à l'activation d'etbr | |
| IL277182A (en) | Compositions and methods for treating Parkinson's disease | |
| EP3973047A4 (fr) | Procédés et compositions pour le traitement de troubles hépatiques | |
| EP3488018A4 (fr) | Procédés et compositions pour l'identification de protéines | |
| EP3701048A4 (fr) | Procédés et compositions pour évaluer et traiter des maladies et des troubles intraoculaires | |
| EP3833340A4 (fr) | Compositions et procédés de traitement de la presbytie | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| EP3634992A4 (fr) | Procédés et compositions pour l'identification d'épitopes | |
| EP3481958A4 (fr) | Procédés et compositions de traitement de troubles et de maladies impliquant rdh12 | |
| EP3735457A4 (fr) | Compositions et procédés pour produire des mégacaryocytes | |
| MA53391A (fr) | Compositions pour l'agriculture et procédés associés | |
| EP3761970A4 (fr) | Compositions et procédés pour le traitement de maladies neurologiques |